Clinical Report: Efficacy and Safety of Hypofractionated vs Conventional Radiotherapy

Overview

This systematic review and meta-analysis compare hypofractionated radiotherapy (HFRT) and conventional fractionated radiotherapy (CFRT) in breast cancer patients. The findings indicate comparable disease-free survival rates and a trend towards reduced acute skin toxicity with HFRT, although significant variability across studies warrants cautious interpretation.

Background

Breast cancer remains a leading cause of cancer-related morbidity and mortality among women globally. Radiotherapy is crucial in reducing recurrence risk post-surgery, and hypofractionated regimens have gained traction due to their potential for similar efficacy with shorter treatment durations. Understanding the comparative effectiveness and safety profiles of HFRT versus CFRT is essential for optimizing treatment strategies.

Data Highlights

Key Findings

• No significant difference in 5-year disease-free survival between HFRT and CFRT (RR = 1.01, P = 0.83).
• No significant difference in lymphedema incidence between HFRT and CFRT (RR = 1.19, P = 0.15).
• HFRT showed a trend towards reduced acute radiation dermatitis compared to CFRT (RR = 1.62, P = 0.002 under fixed-effects model).
• High heterogeneity across studies (I² = 90%) necessitated cautious interpretation of results.
• Standardization of radiation treatments and long-term toxicity evaluation are recommended for future research.

Clinical Implications

Clinicians should consider HFRT as a viable option for early-stage breast cancer, given its comparable efficacy and potential for reduced acute toxicity. However, the variability in study outcomes highlights the need for individualized treatment planning and further research to establish standardized protocols.

Conclusion

HFRT presents a promising alternative to CFRT in breast cancer treatment, with similar oncological outcomes and a potential reduction in acute skin toxicity. Continued investigation into long-term effects and standardization of treatment regimens is essential.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. The ASCO Post, 2020 -- Patient-Reported Functional Outcomes With Hypofractionated vs Conventionally Fractionated Radiotherapy for Nonmetastatic Prostate Cancer
3. The ASCO Post, 2015 -- Hypofractionated Radiotherapy Makes Inroads as Primary Treatment of Prostate Cancer
4. The ASCO Post, 2025 -- Hypofractionated Radiotherapy in Prostate Cancer
5. Postmastectomy Radiation Therapy - American Society for Radiation Oncology (ASTRO)
6. The ASCO Post — Hypofractionated Locoregional RT in Early Breast Cancer
7. ASTRO Guidelines for Postmastectomy Radiation Therapy
8. DEGRO statement on the FAST-Forward trial